Clinician perspectives on cefpodoxime use in respiratory tract infections in India: results from a nationwide survey
DOI:
https://doi.org/10.18203/2349-3933.ijam20262826Keywords:
Antibiotic therapy, Clinical practice, Cefpodoxime, LRTI, RTIs, URTIAbstract
Background: Despite several clinical studies regarding the effectiveness of cefpodoxime in various infections, there is a dearth of studies among clinicians. So, this study aims to assess the perspectives of clinicians on the clinical use and perceived outcomes of cefpodoxime in respiratory tract infections (RTIs) in India.
Methods: A cross-sectional study was conducted among clinicians practicing in routine clinical settings across India. A 22-question structured questionnaire was used to assess respiratory infection management, with a focus on cefpodoxime use, etiology, diagnostic approaches and clinical outcomes. Descriptive statistics were used to summarize responses as frequencies and percentages using Microsoft Excel.
Results: Among 818 clinicians, 51% reported that lower RTIs (LRTIs) are the most commonly encountered infections in their clinical practice. More than half (58.92%) indicated prescribing cefpodoxime primarily for LRTIs. About 59% of respondents stated that both bacterial and viral etiologies contribute to upper RTIs (URTIs) in their practice. Around 53% identified chest X-ray as the most preferred diagnostic modality for Mycoplasma pneumoniae infection in adults. The majority (75.67%) reported cefpodoxime as the most commonly used antimicrobial agent for URTIs. A large proportion (85.82%) indicated cefpodoxime as the preferred oral drug for acute otitis media. Approximately 51% rated cefpodoxime as providing marked improvement on a 5-point global improvement scale.
Conclusions: LRTIs are most prevalent in clinical practice, with cefpodoxime widely used across respiratory indications. Clinicians recognize mixed etiologies in URTIs and prefer chest X-ray for diagnosis. Cefpodoxime demonstrates high usage, favorable outcomes and marked clinical improvement, supporting its effectiveness and utility in routine RTI management.
References
GBD 2019 diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–22.
Jaworski BK, Taylor K, Ramsey KM, Heinz A, Steinmetz S, Pagano I, et al. Exploring Usage of COVID Coach, a Public Mental Health App Designed for the COVID-19 Pandemic: Evaluation of Analytics Data. J Med Internet Res. 2021;23(3):26559.
Teklay G, Yohannes H. Antibiotic prescribing for outpatients with RTIs in public and private clinics of a resource-constrained setting, northern Ethiopia: a cross-sectional study. BMC Infect Dis. 2025;25(1):1436.
GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional and national morbidity, mortality and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191-210.
Grech AK, Foo CT, Paul E, Aung AK, Yu C. Epidemiological trends of respiratory tract pathogens detected via mPCR in Australian adult patients before COVID-19. BMC Infect Dis. 2024;24(1):38.
Calderaro A, Buttrini M, Farina B, Montecchini S, De Conto F, Chezzi C. RTIs and laboratory diagnostic methods: a review with a focus on syndromic panel-based assays. Microorganisms. 2022;10(9):1856.
Huang G, Guo F. Loss of life expectancy due to respiratory infectious diseases: findings from the global burden of disease study in 195 countries and territories 1990-2017. J Popul Res (Canberra). 2022;39(1):1-43.
Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. E Clinical Med. 2021;37:100986.
Avendaño Carvajal L, Perret Pérez C. Epidemiology of Respiratory Infections. Pediatric Resp Diseases. 2020;7:263–72.
Yanagihara K. The role of molecular diagnosis in acute respiratory tract infection. Respiratory Invest. 2019;57(6):511.
Tan T, Little P, Stokes T; Guideline Development Group. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ. 2008;337:437.
Waghmode R, Jadhav S, Nema V. The burden of respiratory viruses and their prevalence in different geographical regions of India: 1970–2020. Front Microbiol. 2021;12:723850.
Santoshi Kumari M, Madhavi J, Bala Krishna N, Raja Meghanadh K, Jyothy A. Prevalence and associated risk factors of otitis media and its subtypes in South Indian population. Egyptian Journal of Ear, Nose, Throat and Allied Sciences. 2016;17(2):57–62.
Hamid O, Abu Dokhan MAA, Gamea A, Ahmed HA. Effectiveness and safety of cefpodoxime in upper RTIs in adult Egyptian population: a report from the Egyptian STAR registry. Egypt J Ear Nose Throat Allied Sci. 2017;18(2):131-5.
Mora R, Salami A, Mora F, Cordone MP, Ottoboni S. Efficacy of cefpodoxime in the prophylaxis of recurrent pharyngotonsillitis. Int J Pediatr Otorhinolaryngol. 2003;67(9):225-8.
Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis. 2007;57(3):S-12.
Hadley JA, Fritsche TR. The role of newer orally administered cephalosporins in contemporary outpatient practice. Diagn Microbiol Infect Dis. 2007;57(1):1–3.
Feldman C, Shaddock E. Epidemiology of lower RTIs in adults. Expert Rev Respir Med. 2019;13(1):63-77.
Pattemore PK, Jennings LC. Epidemiology of Respiratory Infections. Pediatric Resp Med. 2008;5:435–52.
Biscevic-Tokic J, Tokic N, Musanovic A. Pneumonia as the most common lower respiratory tract infection. Med Arch. 2013;67(6):442-5.
Geddes AM. Cefpodoxime proxetil in the treatment of lower RTIs. Drugs. 1991;42(3):34-40.
Klein M. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower RTIs in childhood. International Study Group. Pediatr Infect Dis J. 1995;14(4):19-22.
Aggarwal A, Rath S. Cefpodoxime - utility in RTIs and typhoid fever. Indian J Pediatr. 2004;71(5):413-5.
Talwar D, Vora A, Tarke C, Mehta A, Shah NN, Dalal S. What Makes Cefpodoxime an Empiric Drug of Choice to Treat Lower RTIs, including Acute Exacerbation of Chronic Obstructive Pulmonary Disease, in the Real-world Setting in India. J Assoc Physicians India. 2025;73(10):55-9.
Tobin EH, Thomas M, Bomar PA. Upper RTIs With Focus on The Common Cold. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov. Accessed on 21 January 2026.
Guibas GV, Papadopoulos NG. Viral Upper RTIs. Viral Infections in Children. Indian J Pediatr. 2017;2:1–25.
MacIntyre C, Chughtai AA, Zhang Y, Seale H, Yang P. Viral and bacterial upper respiratory tract infection in hospital health care workers over time and association with symptoms. BMC Infect Dis. 2017;17(1):553.
Kishaba T. Community-Acquired Pneumonia Caused by Mycoplasma pneumoniae: How Physical and Radiological Examination Contribute to Successful Diagnosis. Front Med (Lausanne). 2016;3:28.
Abdulhadi B, Kiel J. Mycoplasma Pneumonia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026. Available at: http://www.ncbi.nlm.nih.gov. Accessed on 21 January 2026.
Miyashita N, Sugiu T, Kawai Y, Oda K, Yamaguchi T, Ouchi K, et al. Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing. BMC Med Imaging. 2009;9:7.
Saraya T, Watanabe T, Tsukahara Y, Ohkuma K, Ishii H, Kimura H, et al. The Correlation between Chest X-ray Scores and the Clinical Findings in Children and Adults with Mycoplasma pneumoniae Pneumonia. Intern Med. 2017;56(21):2845-9.
Sui DX, Ma HC, Wang CC, Shao HY, Xu SH, Fang NN. Diagnostic significance of HRCT imaging features in adult mycoplasma pneumonia: a retrospective study. Sci Rep. 2024;14(1):153.
Jain A, Thacker H, Singh J, Manya S, Gautam A, Padalia H. A Study of Expert Perspectives on the Administration of Cefpodoxime and its Combinations in Respiratory Infections: PERCEPT Survey. J Assoc Physicians India. 2025;73(7):72-8.
Manjula S, Krishna MK. Expert Opinion on the Prescription Practice of Cefpodoxime in the Management of RTIs in Indian Settings. J Adv Med Med Res. 2024;36(6):42-9.
El-Shabrawi MH, Tolba OA, El-Adly TZ. Efficacy and safety of cefpodoxime in the treatment of acute otitis media in children. Egyptian Pediatric Association Gazette. 2016;64(2):81–5.
Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Paediatr Drugs. 2001;3(2):137–58.
Mendelman PM, Del Beccaro MA, McLinn SE, Todd WM. Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media. J Pediatrics. 1992;121(3):459–65.
Buckler R, Mitchell M, Phillips S. Beta-lactams and tetracyclines. In: Side Effects of Drugs Annual. 2020;43:253-63.
Chugh K, Agrawal S. Cefpodoxime: pharmacokinetics and therapeutic uses. Indian J Pediatr. 2003;70:227–31.
Bergogne-Berezin E. Cefpodoxime proxetil in upper RTIs. Drugs. 1991;42(3):25-33.
Akiyama O, Ito T, Ogata M, Okano H, Kabe J, Kawakami M, et al. Clinical evaluation of cefpodoxime proxetil, a new oral cephem, in the treatment of RTIs with the special reference to community-acquired Streptococcus Pneumoniae infections. Jpn J Antibiot. 1995;48(4):522-8.
Downloads
Published
How to Cite
Issue
Section
